Earnings per Share

9 Months Ended

Sep. 27, 2024

Earnings Per Share [Abstract]

Earnings per Share

7. Loss per Share

Loss per share is computed by dividing net loss by the number of weighted-average shares outstanding during the period. A net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per share are the same. If the Company records net income in the future, the denominator of a diluted earnings per share calculation will include both the weighted average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive.

Outstanding equity awards that could potentially dilute per share amounts in the future, but were not included in the computation of diluted per share amounts because to do so would have been antidilutive, were approximately 1.8 million and 1.7 million of contingent value rights held by the Opioid Master Disbursement Trust II and equity awards for the three and nine months ended September 27, 2024 (Successor) and September 29, 2023 (Predecessor), respectively.

The weighted-average number of shares outstanding used in the computations of both basic and diluted loss per share were as follows (in millions):

	Successor	Predecessor
	Three Months Ended September 27, 2024	Three Months Ended September 29, 2023
Basic and diluted	19.7	13.4

	Successor	Predecessor
	Nine Months Ended September 27, 2024	Nine Months Ended September 29, 2023
Basic and diluted	19.7	13.3